Show simple item record

dc.contributor.authorMartinez-Soria, N
dc.contributor.authorMcKenzie, L
dc.contributor.authorDraper, Julia E
dc.contributor.authorPtasinska, A
dc.contributor.authorIssa, H
dc.contributor.authorPotluri, S
dc.contributor.authorBlair, HJ
dc.contributor.authorPickin, A
dc.contributor.authorIsa, A
dc.contributor.authorChin, PS
dc.contributor.authorTirtakusuma, R
dc.contributor.authorColeman, D
dc.contributor.authorNakjang, S
dc.contributor.authorAssi, S
dc.contributor.authorForster, V
dc.contributor.authorReza, M
dc.contributor.authorLaw, E
dc.contributor.authorBerry, P
dc.contributor.authorMueller, D
dc.contributor.authorElder, A
dc.contributor.authorBomken, SN
dc.contributor.authorPal, D
dc.contributor.authorAllan, JM
dc.contributor.authorVeal, GJ
dc.contributor.authorCockerill, PN
dc.contributor.authorWichmann, C
dc.contributor.authorVormoor, J
dc.contributor.authorLacaud, Georges
dc.contributor.authorBonifer, C
dc.contributor.authorHeidenreich, O
dc.date.accessioned2018-12-05T10:35:50Z
dc.date.available2018-12-05T10:35:50Z
dc.date.issued2018en
dc.identifier.citationMartinez-Soria N, McKenzie L, Draper J, Ptasinska A, Issa H, Potluri S, et al. The Oncogenic Transcription Factor RUNX1/ETO Corrupts Cell Cycle Regulation to Drive Leukemic Transformation. Cancer Cell [Internet]. 2018 Oct;34(4):626�642.e8.en
dc.identifier.pmid30300583en
dc.identifier.doi10.1016/j.ccell.2018.08.015en
dc.identifier.urihttp://hdl.handle.net/10541/621367
dc.description.abstractOncogenic transcription factors such as the leukemic fusion protein RUNX1/ETO, which drives t(8;21) acute myeloid leukemia (AML), constitute cancer-specific but highly challenging therapeutic targets. We used epigenomic profiling data for an RNAi screen to interrogate the transcriptional network maintaining t(8;21) AML. This strategy identified Cyclin D2 (CCND2) as a crucial transmitter of RUNX1/ETO-driven leukemic propagation. RUNX1/ETO cooperates with AP-1 to drive CCND2 expression. Knockdown or pharmacological inhibition of CCND2 by an approved drug significantly impairs leukemic expansion of patient-derived AML cells and engraftment in immunodeficient murine hosts. Our data demonstrate that RUNX1/ETO maintains leukemia by promoting cell cycle progression and identifies G1 CCND-CDK complexes as promising therapeutic targets for treatment of RUNX1/ETO-driven AML.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.ccell.2018.08.015en
dc.titleThe Oncogenic Transcription Factor RUNX1/ETO Corrupts Cell Cycle Regulation to Drive Leukemic Transformationen
dc.typeArticleen
dc.contributor.departmentWolfson Childhood Cancer Research Centre, Northern Institute for Cancer Research, Newcastle University, Brewery Lane, Newcastle upon Tyne NE1 7RU, UKen
dc.identifier.journalCancer Cellen
dc.description.noteen]


Files in this item

This item appears in the following Collection(s)

Show simple item record